Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer

Not Applicable

Terminated

Interventions: Procedure: transcranial magnetic stimulation
Procedure: electromyography
Other: survey administration
Drug: sunitinib malate

Brief Summary: The purpose of this research study is to determine how sunitinib (sunitinib malate) causes fatigue. Patients will be asked to complete a brief questionnaire (survey) to rate their levels of fatigue every two weeks while they are participating in this research study. The questionnaire takes approximately 10-15 minutes to complete and is 9 questions. A series of physical measurements for fatigue will be performed before the first dose of sunitinib and again (4) weeks later to see if there are any changes in physical level of fatigues

Detailed Description: PRIMARY OBJECTIVES:

I. To determine the mechanisms associated with sunitinib related fatigue by recording EMG signals during a submaximal elbow contraction, twitch force and TMS prior to and at the end of 4 weeks of sunitinib in metastatic RCC patients.

OUTLINE:

Patients receive sunitinib malate orally (PO) daily for 4 weeks. Patients undergo neuromuscular testing at baseline and on day 28 and complete fatigue assessment at baseline and on days 14 and 28.

.

Recruitment & Eligibility

Inclusion Criteria

Histologically proven renal cell cancer with metastases; pathology from either primary or metastatic tumor; no histologic subtype restriction
Evidence of measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 or evaluable disease
Eastern Cooperative Oncology Group (ECOG) performance score 0 to 1
Hemoglobin >= 9 gram/dL
Common Terminology Criteria for Adverse Events (CTCAE) fatigue levels pre-treatment < 2
Signed and dated informed consent

Exclusion Criteria

Greater than 2 previous systemic treatments for RCC
Heart failure, New York Heart Association (NYHA) class 3 and 4
Unstable angina (defined as ongoing use of nitrates or cardiac ischemia in the prior 6 months)
Arrhythmia uncontrolled by medication
Hypertension (> 160/90 mmHg) not controlled with medical management
Brain metastases or previous cranial radiation, leptomeningeal cancer
Surgery within 2 weeks of study entrance
History of stroke, myasthenia gravis, multiple sclerosis, polyneuropathy
Pregnancy or breast feeding
Central-nervous system active medications, intake or withdrawal of which lowers seizure threshold (determination made in consultation with study's responsible treating physician)
Any history of epilepsy, convulsion or seizure
Medication-resistant epilepsy in a first-degree relative
Cochlear implants or internal pulse generators or cardiac pacemakers or intracardiac lines
Metallic implants in the vicinity of discharging coil in the head or cervical spine
Unexplained fainting spells/syncope or multiple concussions
History of severe head trauma (followed by loss of consciousness)
Implanted brain or spinal cord electrodes/stimulation
Medication infusion device
Frequent/severe headaches or severe migraines
Past or current medical history of diagnosed or undiagnosed tinnitus

Arm && Interventions

Group	Intervention	Description
Supportive care (sunitinib malate, neuromuscular testing)	transcranial magnetic stimulation	Patients receive sunitinib malate PO daily for 4 weeks. Patients undergo neuromuscular testing at baseline and on day 28 and complete fatigue assessment at baseline and on days 14 and 28.
Supportive care (sunitinib malate, neuromuscular testing)	electromyography	Patients receive sunitinib malate PO daily for 4 weeks. Patients undergo neuromuscular testing at baseline and on day 28 and complete fatigue assessment at baseline and on days 14 and 28.
Supportive care (sunitinib malate, neuromuscular testing)	survey administration	Patients receive sunitinib malate PO daily for 4 weeks. Patients undergo neuromuscular testing at baseline and on day 28 and complete fatigue assessment at baseline and on days 14 and 28.
Supportive care (sunitinib malate, neuromuscular testing)	sunitinib malate	Patients receive sunitinib malate PO daily for 4 weeks. Patients undergo neuromuscular testing at baseline and on day 28 and complete fatigue assessment at baseline and on days 14 and 28.

Primary Outcome Measures

Name	Time	Method
Changes of Muscular (Peripheral) Fatigue Maximal Twitch Force (MTF)	Baseline and 28 days	The MTF will be elicited by supramaximal-intensity electrical stimulation of the muscle before and after the sustained contraction (SC). If the muscle is fatigued at the end of the SC, the MTF will be reduced because the ability of muscle to generate force declines with fatigue. If the sunitinib treatment results in minimal muscular fatigue, the MTF will not have as much reduction in the 2nd as that in the 1st session.
Change in EMG Amplitude and Power Frequency	Baseline and 28 days	EMG amplitude will increase (for low-intensity SC) and mean power frequency (MPF) decrease with muscle fatigue. The EMG signals recorded during the SC, its amplitude and MPF will be analyzed to determine their changes at the end vs. beginning of the SC. If the sunitinib results in minimal muscular fatigue, the amount of EMG increase and MPF decrease will be reduced in the 2nd compared with those the 1st session.
Changes in Motor Evoked Potential (MEP) by TMS	Baseline and 28 days	TMS illustrates the changes in corticospinal excitability occurring in association with fatigue. Central muscle evoked response (MEP) will be elicited using transcranial magnetic stimulation (TMS) using single stimulus pulses applied to the scalp overlying the primary motor cortex.